Thyroid cancer staging and genomics.

Kim et al . have published a very interesting article in World Journal of Surgery about staging of thyroid cancer and implications of genomic analysis based on patients’ age (1). The authors compared overall survival and recurrencefree survival with different age cutoff values, and they investigated the appropriateness of the new staging system at a genomic level. They studied 505 patients for the clinical information (low-to intermediate-risk papillary thyroid cancers with 28 recurrences and 14 deaths) and The Cancer Genome Atlas (TCGA) data. They were able to show significant values using 55 years as a cutoff for relapse-free survival. Signaling pathway analysis revealed that patients above age 55 had differing genetic pathways associated with aggressiveness of thyroid cancer.

[1]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[2]  I. Ganly,et al.  Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[3]  Dong Jin Lee,et al.  The Updated AJCC/TNM Staging System for Papillary Thyroid Cancer (8th Edition): From the Perspective of Genomic Analysis , 2018, World Journal of Surgery.

[4]  E. Mazzaferri,et al.  Increasing Incidence of Thyroid Cancer in the United States, 1973–2002Davies L, Welch HG (Dept of Veterans Affairs Med Ctr, White River Junction, Vt; Darmouth Med School, Hanover, NH) JAMA 295:2164–2167, 2006§ , 2007 .

[5]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[6]  Gerard M Doherty,et al.  Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[7]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[8]  Z. Hall.  Cancer , 1906, The Hospital.

[9]  J. Shah,et al.  Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer , 2016, Annals of Surgical Oncology.

[10]  J. Shah,et al.  An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer. , 2016, Thyroid : official journal of the American Thyroid Association.

[11]  J. Shah,et al.  Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer , 2019, Surgery.